China CRO – George Clinical

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

By George Clinical
Industry News

9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]

China’s dynamism requires a nimble CRO with extensive research networks

China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s most populous nation (and second largest economy) continues to mature, so does their regulatory requirements. These regulatory adjustments pose a risk to sponsors […]